Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Bodenlenz, M; Ellmerer, M; Schaupp, L; Jacobsen, LV; Plank, J; Brunner, GA; Wutte, A; Aigner, B; Mautner, SI; Pieber, TR.
Bioavailability of insulin detemir and human insulin at the level of peripheral interstitial fluid in humans, assessed by open-flow microperfusion.
Diabetes Obes Metab. 2015; 17(12):1166-1172
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Bodenlenz Manfred
Brunner Gernot
Ellmerer Martin
Mautner Selma
Pieber Thomas
Sadoghi Birgit
Schaupp Lukas
Wutte Andrea Maria

Dimensions Citations:

Plum Analytics:
To find an explanation for the lower potency of insulin detemir observed in humans compared with unmodified human insulin by investigating insulin detemir and human insulin concentrations directly at the level of peripheral insulin-sensitive tissues in humans in vivo. Euglycaemic-hyperinsulinaemic clamp experiments were performed in healthy volunteers. Human insulin was administered i.v. at 6 pmol/kg/min and insulin detemir at 60 pmol/kg/min, achieving a comparable steady-state pharmacodynamic action. In addition, insulin detemir was doubled to 120 pmol/kg/min. Minimally invasive open-flow microperfusion (OFM) sampling methodology was combined with inulin calibration to quantify human insulin and insulin detemir in the interstitial fluid (ISF) of subcutaneous adipose and skeletal muscle tissue. The human insulin concentration in the ISF was ∼115 pmol/l or ∼30% of the serum concentration, whereas the insulin detemir concentration in the ISF was ∼680 pmol/l or ∼2% of the serum concentration. The molar insulin detemir interstitial concentration was five to six times higher than the human insulin interstitial concentration and metabolic clearance of insulin detemir from serum was substantially reduced compared with human insulin. OFM proved useful for target tissue measurements of human insulin and the analogue insulin detemir. Our tissue data confirm a highly effective retention of insulin detemir in the vascular compartment. The higher insulin detemir relative to human insulin tissue concentrations at comparable pharmacodynamics, however, indicate that the lower potency of insulin detemir in humans is attributable to a reduced effect in peripheral insulin-sensitive tissues and is consistent with the reduced in vitro receptor affinity. © 2015 John Wiley & Sons Ltd.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Biological Availability -
Calibration -
Cross-Over Studies -
Dose-Response Relationship, Drug -
Extracellular Fluid - metabolism
Glucose Clamp Technique -
Humans -
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - blood
Hypoglycemic Agents - metabolism
Hypoglycemic Agents - pharmacokinetics
Infusions, Intravenous -
Insulin Detemir - administration & dosage
Insulin Detemir - blood
Insulin Detemir - metabolism
Insulin Detemir - pharmacokinetics
Insulin, Regular, Human - administration & dosage
Insulin, Regular, Human - blood
Insulin, Regular, Human - metabolism
Insulin, Regular, Human - pharmacokinetics
Inulin - administration & dosage
Inulin - blood
Inulin - metabolism
Inulin - pharmacokinetics
Lipoylation -
Male -
Metabolic Clearance Rate -
Muscle, Skeletal - metabolism
Subcutaneous Fat - metabolism
Tissue Distribution -
Young Adult -

Find related publications in this database (Keywords)
adipose tissue
clinical trial
insulin analogues
© Meduni Graz Impressum